University Hospitals' Deepgen HIV assay will use Advanced Biological Laboratories' DeepChek software to help monitor drug resistance and minority variants in HIV strains.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
With the precision of PCR, the method could ultimately be used to build faster, simpler diagnostics.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
The platform — called NINA for non-instrumented nucleic acid amplification — is designed to work with a wide range of isothermal amplification methods.
Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.
The firm said the product is the first HIV viral load assay with a dual claim for diagnosis and treatment monitoring.
MOgene, a genomics services provider, launched a new subsidiary this week called MOgene Clinical Diagnostics (MOgeneDx) to provide next-generation sequencing-based testing for infectious diseases and immune disorders.
Two new studies demonstrate improved methods using droplet digital PCR to detect very low viral loads in HIV-positive patients, pushing the detection threshold lower than that of real-time PCR.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.